INNsight Newsletter - April edition
Welcome to the April edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.?
This month's thought leadership includes:
Pharma Deals Review of 2023
The whitepaper highlights a significant downturn in the life sciences sector’s deal activity, with a 27% decline in both M&A and licensing deals compared to 2022, driven by market volatility and increased capital costs. It notes a 36% reduction in collaborative R&D alliances, marking a 5-year low, as companies narrowed their focus on therapeutic areas. These insights suggest a cautious approach to deal-making and a strategic reprioritization within the industry.?Read more
领英推荐
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
In this report, we characterize the current state of these therapies across the product lifecycle, beginning with pre-commercial activities such as funding and clinical research. We also detail the hurdles to commercialization, including infrastructure needs, reimbursement, and patient access.??It also provides potential future scenarios across eight indicators to understand the evolution of the sector through 2035 and beyond.? Read more
Seeking New Horizons:??Where Innovators Find Opportunities In A Fast-Changing Immunology Landscape
Immunology has been a powerhouse for the biopharmaceutical industry, growing at a rate 3-5 times faster than the overall pharmaceutical market and is projected to hit $166 billion by the end of 2024. However, the sector is facing a slowdown, with growth expected to decelerate from a 15% compound annual growth rate (CAGR) to just 2-5% over the next five years, falling below the industry average for the first time. Read more
To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link .